Abstract:BackgroundGastric cancer (GC) remains a common disease with a poor prognosis worldwide. The SET binding protein 1 (SETBP1) has been implicated in the pathogenesis of several cancers and plays a dual role as an oncogene and a tumor suppressor gene. However, the role and underlying mechanism of SETBP1 in GC remain unclear.Materials and MethodsWe used next-generation RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) to explore the correlation between SETBP1 expression and tumor progression. We then quantified SETBP1 expression in GC cells with real-time quantitative polymerase chain reactions (RT-qPCR). The chi-square test and logistic regression were used to assess the correlation between SETBP1 expression and clinicopathological features. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to assess the relationship between SETBP1 expression and survival. Finally, gene set enrichment analyses (GSEA) were used to examine GC-related signaling pathways in low and high SETBP1 expressing samples.ResultsWe found SETBP1 expression levels in GC tissues to be significantly lower than in adjacent non-tumor tissues in the TCGA database. In addition, SETBP1 expression differed significantly between groups classified by tumor differentiation. Furthermore, SETBP1 expression in diffuse-type GC was significantly higher than in intestinal-type GC. However, it did not differ significantly across pathological- or T-stage groups. RT-qPCR and comprehensive meta-analysis showed that SETBP1 expression is downregulated in GC cells and tissues. Interestingly, SETBP1 expression in poorly- or un-differentiated GC cells was higher than in well-differentiated GC cells. Moreover, the chi-square test and logistic regression analyses showed that SETBP1 expression correlates significantly with tumor differentiation. Kaplan–Meier curves indicated that patients with relatively high SETBP1 expression had a poor prognosis. Multivariate analyses indicated that SETBP1 expression might be an important predictor of poor overall survival in GC patients. GSEA indicated that 20 signaling pathways were significantly enriched in samples with high and low SETBP1 expression.ConclusionSETBP1 may play a dual role in GC progression.

SET Nuclear Proto-Oncogene Gene Expression is Associated with Microsatellite Instability in Human Colorectal Cancer Identified by Co-Expression Analysis.

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

Cmar_a_255930 4735..4745

Identification of Key Genes and Pathways Involved in Microsatellite Instability in Colorectal Cancer

MiR-502/SET8 regulatory circuit in pathobiology of breast cancer.

SET facilitates immune escape of microsatellite stability colorectal cancer by inhibiting c‐Myc degradation

MiR-502/SET8 Regulatory Circuit in Pathobiology of Breast Cancer

High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma

Involvement of Set in the Wnt Signaling Pathway and the Development of Human Colorectal Cancer

The Set Gene is a Potential Oncogene in Human Colorectal Adenocarcinoma and Oral Squamous Cell Carcinoma

Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation Through the STAT1-CCND1/CDK6 Axis.

SE translation mRNA overexpression: a potential prognostic predictor in breast cancer

Identification Of Potential Biomarkers For Risk Analysis Of Colorectal Cancer Using A Combined Bioinformatics Analysis

The Role of SETBP1 in Gastric Cancer: Friend or Foe

Expression of set gene in colorectal adenocarcinoma

Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer

Histone-lysine N-methyltransferase SETD7 is a Potential Serum Biomarker for Colorectal Cancer Patients

Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis.

SETDB1 Promotes Gastric Carcinogenesis and Metastasis Via Upregulation of CCND1 and MMP9 Expression.

The Identification of a Common Different Gene Expression Signature in Patients with Colorectal Cancer

Increased Expression of SET Domain-Containing Proteins and Decreased Expression of Rad51 in Different Classes of Renal Cell Carcinoma